2017
DOI: 10.1007/s10120-017-0751-4
|View full text |Cite
|
Sign up to set email alerts
|

Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis

Abstract: After PSM, standardized follow-up by a specialized center significantly improved OS. Cross-sectional imaging and treatment of recurrence were associated with better outcome. Regular follow-up by cross-sectional imaging especially during the first 3 years should be recommended by national guidelines, since early detection might help select patients for treatment of recurrence and even resection in few designated cases.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
23
1
4

Year Published

2017
2017
2020
2020

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 42 publications
(30 citation statements)
references
References 74 publications
(106 reference statements)
2
23
1
4
Order By: Relevance
“…A structured follow-up of MSI-H gastric cancer patients could be useful, allowing an early (local or systemic) intervention at the time of relapse. 36 In conclusion our study confirmed a superior outcome of MSI-H gastric cancer patients treated with neoadjuvant systemic therapy in comparison to MSS patients, despite a poor histological response in the resected tumor tissue of MSI-H patients. Together with the long-term outcome in several relapsed patients, these observations call for future prospective trials accounting for the MSI status of gastric cancer patients.…”
Section: Discussionsupporting
confidence: 78%
See 1 more Smart Citation
“…A structured follow-up of MSI-H gastric cancer patients could be useful, allowing an early (local or systemic) intervention at the time of relapse. 36 In conclusion our study confirmed a superior outcome of MSI-H gastric cancer patients treated with neoadjuvant systemic therapy in comparison to MSS patients, despite a poor histological response in the resected tumor tissue of MSI-H patients. Together with the long-term outcome in several relapsed patients, these observations call for future prospective trials accounting for the MSI status of gastric cancer patients.…”
Section: Discussionsupporting
confidence: 78%
“…Give the non‐randomized design it is unknown whether metastatic MSI‐H gastric cancer patients have a favorable outcome per se or whether a surgical intervention could contribute to a better survival. A structured follow‐up of MSI‐H gastric cancer patients could be useful, allowing an early (local or systemic) intervention at the time of relapse …”
Section: Discussionmentioning
confidence: 99%
“…Numerous malignancies, such as lung, gastroesophageal, and colorectal cancers, have well‐established post‐operative surveillance recommendations to guide the clinician and facilitate an early diagnosis of tumor recurrence . The challenge in developing such guidelines however lies in the diversity of the tumor biology and behavior of these various malignancies: surveillance strategies that are too lax may miss early recurrences that could be potentially treatable and surveillance proposals that are too strict may over‐test patients leading to increased costs to the healthcare system without providing a survival advantage.…”
Section: Introductionmentioning
confidence: 99%
“…The cornerstone of therapy for many solid organ malignancies is curative-intent surgical resection, but unfortunately, a significant Numerous malignancies, such as lung, gastroesophageal, and colorectal cancers, have well-established post-operative surveillance recommendations to guide the clinician and facilitate an early diagnosis of tumor recurrence. [1][2][3][4][5] The challenge in developing such guidelines however lies in the diversity of the tumor biology and behavior of these various malignancies: surveillance strategies that are too lax may miss early recurrences that could be potentially treatable and surveillance proposals that are too strict may over-test patients leading to increased costs to the healthcare system without providing a survival advantage. For most malignancies, the evidence for follow-up regimens is scant and significant questions remain 6,7 : Is routine monitoring superior to selective assessment?…”
Section: Introductionmentioning
confidence: 99%
“…Insgesamt rezidivieren 30-40 % der Magenkarzinome nach kurativ intendierter Therapie, davon über 90 % innerhalb der ersten drei Jahre [1, [10][11][12]. Die häufigste Rezidivlokalisation ist peritoneal, gefolgt von hepatischen Metastasen und lokoregionären Rezidiven.…”
Section: Statistikunclassified